Plasmodium Vivax Clinical Trial
Official title:
Phenotyping and Genotyping of Duffy Antigen
Malaria remains the world's leading parasitic endemic. Almost half of the world's population lives in endemic areas. Many at-risk people in African countries remain without access to malaria control. Malaria kills approximately 400,000 people each year, most of whom are children under the age of 5 in Africa. Since 2005, an increasing number of Plasmodium vivax infections have been observed in Duffy-negative populations in South America and Africa, calling into question the essential role of the PvDBP-DARC interaction. The objective of the investigators is therefore to study and understand the invasion pathways used by Plasmodium vivax in Duffy-negative subjects.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT01290601 -
Study to Evaluate the Efficacy and Safety of Tafenoquine for the Treatment of Plasmodium Vivax in Adults
|
Phase 2 | |
| Recruiting |
NCT02610686 -
Evaluating the Efficacy of Chloroquine for the Treatment of Plasmodium Vivax Infections in Central Vietnam
|
Phase 4 | |
| Terminated |
NCT04445103 -
The Malaria Heart Disease Study
|
||
| Recruiting |
NCT02364583 -
Investigation of Short Course, High Dose Primaquine Treatment for Liver Stages of Plasmodium Vivax Infection
|
Phase 4 | |
| Completed |
NCT02802813 -
P.Vivax Treatment Trial
|
Phase 1/Phase 2 | |
| Completed |
NCT01157897 -
Study of VMP001 and AS01B (Adjuvant Formulation) in Healthy Malaria-Naïve Adults
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT06392152 -
Efficacy of Focal Primaquine Mass Administration for Eliminating Plasmodium Vivax Malaria in Northern Myanmar
|
N/A | |
| Recruiting |
NCT04411836 -
Effectiveness of Novel Approaches to Radical Cure With Tafenoquine and Primaquine
|
Phase 3 | |
| Completed |
NCT01816113 -
Phase Ia Study of ChAd63/MVA PvDBP
|
Phase 1 |